publication date: Mar. 29, 2019
Clinical Roundup Fulvestrant plus Anastrozole extends lives of women with advanced HR+ breast cancer
Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, compared with treatment with anastrozole alone, according to results of a SWOG Cancer Research Network study appearing in the New England Journal of Medicine.
These study results provide the most promising evidence to date of a life-extending first line of treatment for the advanced form of hormone receptor-positive breast cancer, which accounts for about two out of every three cases of breast cancer diagnosed in the United States, according to American Cancer Society statistics.
“These results are very exciting,” said Rita Mehta, a member SWOG’s breast cancer research committee, a clinical professor at the University of California Irvine, and the medical director of the Breast Center at Chao Family Comprehensive Cancer Center.
“Women who recieved fulvestrant, right up front, live longer based on this new long-term analysis,” Mehta said. “This is credible evidence that combination endocrine therapy should be considered an option for first-line treatment of advanced hormone receptor-positive breast cancer.”
The new results report the final survival outcomes of women who volunteered to participate in S0226, the SWOG trial led by Mehta. Original results, published in the New England Journal of Medicine … Continue reading Fulvestrant plus Anastrozole extends lives of women with advanced HR+ breast cancer
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.